Gritstone bio, Inc. entered into a securities purchase agreement to issue 6,637,165 common shares at a price of $2.26 per common share for gross proceeds of $14,999,992.9, 13,274,923 pre-funded warrants at a price of $2.2599 per pre-funded warrant for gross proceeds of $29,999,998.487; for aggregate gross proceeds of $44,999,991.387 on October 24, 2022. The transaction will include participation from lead investor Redco II Master Fund, L.P., a fund managed by returning investor Redmile Group, LLC for 13,274,923 pre-funded warrants for gross proceeds of $29,999,998.487; and returning investor Gilead Sciences, Inc. for 1,769,911 shares for gross proceeds of $3,999,998.86, Invus Public Equities, L.P., a fund managed by The Invus Group, LLC for 1,106,194 shares for gross proceeds of $2,499,998.44, Hercules Capital, Inc. for 442,477 shares for gross proceeds of $999,998.02, Altium Capital Management LP for 663,716 shares for gross proceeds of $1,499,998.16, Point72 Associates, LLC, a fund managed by S.A.C. Capital Management, LLC for 2,654,867 shares for gross proceeds of $5,999,999.42 for common shares. The company issued pre-funded warrants to purchase up to 13,274,923 common shares.

Each pre-funded warrant will have an exercise price of $0.0001 per share, will be exercisable immediately, and will be exercisable until exercised in full. The transaction is expected to close on October 27, 2022, subject to customary closing conditions.